Tag - Raymond James

Profound Medical

RJ ups Profound Medical to strong buy

Raymond James upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “strong buy” from “outperform” with a price target of $20.00, after pricing-in the TULSA-PRO system’s 2025 sales inflection. At mid-day on September 18...

Euprxia Logo

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

Raymond James upgraded Eupraxia Pharmaceuticals (TSX:EPRX) to “strong buy” from “outperform” and maintained its price target of $11 (Canadian). The stock was quoted at $6.99, up 15 cents at midday on May 18. Pointing to...


RJ starts WELL Health at OP; PT $8.50 (Canadian)

Raymond James initiated coverage of WELL Health Technologies (TSX:WELL) with an “outperform” rating and price target of $8.50 (Canadian). The stock closed at $5.46 on April 27. WELL Health operates a hybrid care...